Mr. Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience across the biotechnology, pharmaceutical and healthcare sectors. Most recently, he served as Chief Financial Officer and Head of Business Development at Inozyme Pharma, where he oversaw finance, investor relations, business development and legal functions and led the company's acquisition by BioMarin Pharmaceutical. Previously, he served as Chief Financial Officer and Head of Corporate Development at Ocugen. Earlier in his career, he held finance leadership positions at Aralez Pharmaceuticals, Bausch Health Companies, and General Motors. He holds an M.B.A. from the MIT Sloan School of Management, master's degrees from MIT and The Ohio State University, and a bachelor's degree in mechanical engineering from the Indian Institute of Technology Madras.

In connection with his appointment, on September 9, 2026, Mr. Subramanian was granted an option to purchase 100,000 shares of SCYNEXIS common stock, at a per share exercise price of $4.91, the closing trading price on September 9, 2026. The stock option has a ten-year term and vests over four years, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the date of grant and the remainder vesting in equal monthly installments over the following thirty-six months, provided Mr. Subramanian continues to provide service to SCYNEXIS. The stock option was granted pursuant to the SCYNEXIS 2015 Inducement Award Plan and as a material inducement to Mr. Subramanian entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).